Positron Emission Tomography As a Method for Measuring Drug Delivery to Tumors in Vivo: The Example of [(11)C]docetaxel

Overview

Journal Front Oncol

Specialty Oncology

Date 2013 Aug 30

PMID 23986880

Citations 9

Authors

Astrid A M van der Veldt

Egbert F Smit

Adriaan A Lammertsma

Affiliations

Soon will be listed here.

Abstract

Systemic anticancer treatments fail in a substantial number of patients. This may be caused by inadequate uptake and penetration of drugs in malignant tumors. Consequently, improvement of drug delivery to solid tumors may enhance its efficacy. Before evaluating strategies to enhance drug uptake in tumors, better understanding of drug delivery to human tumors is needed. Positron emission tomography (PET) is an imaging technique that can be used to monitor drug pharmacokinetics non-invasively in patients, based on radiolabeling these drugs with short-lived positron emitters. In this mini review, principles and potential applications of PET using radiolabeled anticancer drugs will be discussed with respect to personalized treatment planning in oncology. In particular, it will be discussed how these radiolabeled anticancer drugs could help to develop strategies for improved drug delivery to solid tumors. The development and clinical implementation of PET using radiolabeled anticancer drugs will be illustrated by validation studies of carbon-11 labeled docetaxel ([(11)C]docetaxel) in lung cancer patients.

Citing Articles

Phase 0 trials/ Intra-Target-Microdosing (ITM) and the lung: a review.

Quinn T, Bruce A, Burt T, Dhaliwal K BMC Pulm Med. 2024; 24(1):425.

PMID: 39210357 PMC: 11363577. DOI: 10.1186/s12890-024-03193-5.

A review of frustrated Lewis pair enabled monoselective C-F bond activation.

Lye K, Young R Chem Sci. 2024; 15(8):2712-2724.

PMID: 38404400 PMC: 10882520. DOI: 10.1039/d3sc06485a.

The role of clinical imaging in oncology drug development: progress and new challenges.

Murphy P, Galette P, Van der Aart J, Janiczek R, Patel N, Brown A Br J Radiol. 2023; 96(1150):20211126.

PMID: 37393537 PMC: 10546429. DOI: 10.1259/bjr.20211126.

Phase 0/microdosing approaches: time for mainstream application in drug development?.

Burt T, Young G, Lee W, Kusuhara H, Langer O, Rowland M Nat Rev Drug Discov. 2020; 19(11):801-818.

PMID: 32901140 DOI: 10.1038/s41573-020-0080-x.

[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.

de Jong E, van Elmpt W, Leijenaar R, Hoekstra O, Groen H, Smit E Eur J Nucl Med Mol Imaging. 2016; 44(1):8-16.

PMID: 27600280 PMC: 5121177. DOI: 10.1007/s00259-016-3498-y.

References

Cai W, Chen K, He L, Cao Q, Koong A, Chen X . Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007; 34(6):850-8. DOI: 10.1007/s00259-006-0361-6. View

Gambhir S . Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002; 2(9):683-93. DOI: 10.1038/nrc882. View

Propper D, de Bono J, Saleem A, Ellard S, Flanagan E, Paul J . Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J Clin Oncol. 2003; 21(2):203-10. DOI: 10.1200/JCO.2003.02.008. View

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

Boellaard R, van Lingen A, van Balen S, Hoving B, Lammertsma A . Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med. 2001; 28(1):81-9. DOI: 10.1007/s002590000405. View

Jain R . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7(9):987-9. DOI: 10.1038/nm0901-987. View

van der Veldt A, Hendrikse N, Smit E, Mooijer M, Rijnders A, Gerritsen W . Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imaging. 2010; 37(10):1950-8. PMC: 2933032. DOI: 10.1007/s00259-010-1489-y. View

Sorger D, Patt M, Kumar P, Wiebe L, Barthel H, Seese A . [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol. 2003; 30(3):317-26. DOI: 10.1016/s0969-8051(02)00442-0. View

Inoue T, Kim E, Wallace S, Yang D, Wong F, Bassa P . Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm. 1996; 11(4):235-45. DOI: 10.1089/cbr.1996.11.235. View

10.

van der Veldt A, Lammertsma A, Hendrikse N . [11C]docetaxel and positron emission tomography for noninvasive measurements of docetaxel kinetics. Clin Cancer Res. 2007; 13(24):7522. DOI: 10.1158/1078-0432.CCR-07-1626. View

11.

Shields A, Grierson J, Dohmen B, Machulla H, Stayanoff J, Obradovich J . Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998; 4(11):1334-6. DOI: 10.1038/3337. View

12.

Kil K, Ding Y, Lin K, Alexoff D, Kim S, Shea C . Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol. 2007; 34(2):153-63. PMC: 2866181. DOI: 10.1016/j.nucmedbio.2006.11.004. View

13.

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

14.

Latreille J, Gelmon K, Hirsh V, Laberge F, Maksymiuk A, Shepherd F . Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest New Drugs. 1999; 16(3):265-70. DOI: 10.1023/a:1006126505910. View

15.

van der Veldt A, Luurtsema G, Lubberink M, Lammertsma A, Hendrikse N . Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. Curr Pharm Des. 2008; 14(28):2914-31. DOI: 10.2174/138161208786404344. View

16.

van der Veldt A, Smit E . Bevacizumab in neoadjuvant treatment for breast cancer. N Engl J Med. 2012; 366(17):1637. DOI: 10.1056/NEJMc1202229. View

17.

Harte R, Matthews J, OReilly S, Tilsley D, Osman S, Brown G . Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. J Clin Oncol. 1999; 17(5):1580-8. DOI: 10.1200/JCO.1999.17.5.1580. View

18.

Nagengast W, de Vries E, Hospers G, Mulder N, de Jong J, Hollema H . In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007; 48(8):1313-9. DOI: 10.2967/jnumed.107.041301. View

19.

van der Veldt A, Lubberink M, Mathijssen R, Loos W, Herder G, Greuter H . Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography. Clin Cancer Res. 2013; 19(15):4163-73. DOI: 10.1158/1078-0432.CCR-12-3779. View

20.

Slobbe P, Poot A, Windhorst A, van Dongen G . PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET. Drug Discov Today. 2012; 17(21-22):1175-87. DOI: 10.1016/j.drudis.2012.06.016. View